<code id='60232EC240'></code><style id='60232EC240'></style>
    • <acronym id='60232EC240'></acronym>
      <center id='60232EC240'><center id='60232EC240'><tfoot id='60232EC240'></tfoot></center><abbr id='60232EC240'><dir id='60232EC240'><tfoot id='60232EC240'></tfoot><noframes id='60232EC240'>

    • <optgroup id='60232EC240'><strike id='60232EC240'><sup id='60232EC240'></sup></strike><code id='60232EC240'></code></optgroup>
        1. <b id='60232EC240'><label id='60232EC240'><select id='60232EC240'><dt id='60232EC240'><span id='60232EC240'></span></dt></select></label></b><u id='60232EC240'></u>
          <i id='60232EC240'><strike id='60232EC240'><tt id='60232EC240'><pre id='60232EC240'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:8226
          A stethoscope lays on banknotes next to a calculator, all on top of a insurance application form — coverage from STAT
          Adobe

          Major insurance companies like UnitedHealthcare and Humana have edged out private equity firms from investing in Medicare Advantage, according to a new report.

          But investors have found pockets of profits by backing companies involved in enrolling seniors in MA plans and keeping track of them once they’re there. They’re investing in insurance brokerages, marketers, in-home assessment companies, and “insurtechs,” the report said, based on a new analysis of deals in the space since 2016.

          advertisement

          Overall, private equity investors made only 4 investments in Medicare Advantage-related companies last year, compared with 12 in 2022, down from a peak of 19 in 2021, per the Private Equity Stakeholder Project, a group focused on holding private equity firms accountable for their impacts on people and the planet, according to its website.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Hospitals look to new technology to keep health care workers safe
          Hospitals look to new technology to keep health care workers safe

          AdobeOnedayinearly2020,justweeksbeforePhiladelphiaenteredlockdown,ThomasJeffersonUniversity’spublics

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

          INAFASSBENDER/AFPviaGettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup tog